Dapagliflozin as Prophylaxis for Glucocorticoid-Induced Hyperglycemia
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to investigate whether dapagliflozin can help prevent glucocorticoid-induced hyperglycemia (GIH) in hospitalized patients requiring high-dose glucocorticoids (GCs). This trial will also assess the safety of dapagliflozin when used alongside GCs. The main questions the trial aims to answer are:
Does dapagliflozin reduce the incidence of GIH in patients receiving high-dose GCs? What side effects or adverse events occur in patients taking dapagliflozin alongside high-dose GCs? Researchers will compare dapagliflozin to standard glucose monitoring (SGM) to determine if dapagliflozin is effective in preventing GIH in patients receiving high doses of GCs.
Participants will:
Take dapagliflozin (10 mg/day) or undergo standard glucose monitoring during their hospital stay.
Visit the hospital for regular check-ups and glucose testing during their treatment.
Record their glucose levels multiple times a day and report any adverse events they experience.